Mumps Virus Vaccine Live
drug drugOn this page
Also known as Mumps vaccineMumps vaccine (live attenuated)Mumps virus live antigenaMumps virus vaccineliveMumpslive attenuatedMumpsvaxVirus mumps (jeryl lynn strain)
Summary
Mumps Virus Vaccine Live (CHEMBL2109201) is a phase-3 clinical-stage vaccine component (ATC J07BE01); indicated across 3 conditions including meningococcal infection and mumps infectious disease.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Vaccine component
- ATC class: J07BE01
- Indications: 3 conditions
- Clinical trials: 2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109201 |
| Name | Mumps Virus Vaccine Live |
| Type | Vaccine component |
| Max phase | 3 |
| ATC | J07BE01 |
Also known as: Mumps vaccine, Mumps vaccine (live attenuated), Mumps virus live antigen, a, Mumps virus vaccine live, Mumps virus vaccine, live, Mumps, live attenuated, Mumpsvax, Virus mumps (jeryl lynn strain), MUMPS VIRUS VACCINE LIVE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| meningococcal infection | 3 | MONDO:0005373 | EFO:0004249 |
| mumps infectious disease | 3 | MONDO:0000989 | EFO:0007383 |
| measles | 2 | MONDO:0004619 | EFO:1002025 |
Clinical trials
Total trials: 2.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04364399 | PHASE4 | COMPLETED | Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine |
| NCT06208683 | PHASE4 | UNKNOWN | The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: meningococcal infection, mumps infectious disease, measles